BioCentury
ARTICLE | Clinical News

EC approves Bioepis' Humira biosimilar

September 1, 2017 3:15 PM UTC

Samsung Bioepis Co. Ltd. said the European Commission approved Imraldi (SB5), a biosimilar of autoimmune drug Humira adalimumab. The biosimilar is indicated to treat psoriasis, Crohn's disease, rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, hidradenitis suppurativa, ulcerative colitis and uveitis.

Imraldi is Bioepis' third anti-tumor necrosis factor (TNF) biosimilar to receive EU approval. Last year, the EC approved Benepali (SB4), a biosimilar of Enbrel etanercept, and Flixabi (SB2), a biosimilar of Remicade infliximab (see BioCentury, Jan. 25, 2016 & June 6, 2016)...